FORMULATION, OPTIMIZATION, AND CHARACTERIZATION OF TRANSDERMAL DRUG DELIVERY SYSTEMS CONTAINING EPLERENONE

RAMESH SHINDE; MALARKODI VELRAJ

doi:10.22159/ijap.2022v14i1.42827

Authors

RAMESH SHINDE Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India, Chennai, Tamilnadu, India
MALARKODI VELRAJ Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India, Chennai, Tamilnadu, India

DOI:

https://doi.org/10.22159/ijap.2022v14i1.42827

Keywords:

TDDS, Eplerenone, ERS 100, In vivo skin irritation study

Abstract

Objective: The proposed work was aimed at optimization, formulation, and characterization of transdermal patches of eplerenone for efficient transdermal delivery of the drug.

Methods: The log p estimation of eplerenone is 1.34, it was closer to standard worth. Log P value in a range of 1 to 4 indicates higher permeation through the skin. FTIIR study was carried out individually for drug, each polymer, and finished product (Patches) compared eplerenone and FTIR spectra of pure drug and polymer. The calibration curve of eplerenone in Phosphate buffer pH 6.8 was analyzed.

Results: The selected range of eplerenone was found to be linear. A regression coefficient (R²) at 245 nm was found to be 0.994. Drug content outcomes additionally discovered uniform in all clusters in a range of 97 % to 98 %, that batches arranged with ERS 100 show great mechanical properties contrast with different polymers however helpless glue properties. The flatness of 4 cm² patches ranges from 348±0.087 mg to 387±0.527 mg. skin irritation it was produced irritation with negligible erythema following 10 d and unequivocal erythema, promptly obvious edema was produced following 12 d.

Conclusion: These after-effects of the in vivo skin irritation study recommended that advanced batch S9 doesn't show any kind of significant disturbance on rodent skin for as long as 14 d and it was securely utilized around 24 h. the optimized batch S9 drug was constantly discharged through the Wistar rodent skin up to 16 hr and the delivery design was like an in vitro dissolution profile of the market product.

Downloads

Download data is not yet available.

References

Oza NA, Sahu AR, Patel DM, Patel PU, Patel LD, Koshia HG. Studies on optimization of the reservoir-type transdermal patch using carvedilol using 32 full factorial designs. Int J Res Med. 2013 Sep;2(4):84Ǧ89.

Brajesh M, Naina K, Shashank S. Quantitative determination of eplerenone in bulk drug and tablet dosage form by TLC/densitometry. Int J Pharm Life Sci. 2011 Jun;2:502-5.

Stier CT. Eplerenone: a selective aldosterone blocker. Cardiovasc Drug Rev. 2003 Feb;21(3):169-84. doi: 10.1111/j.1527-3466.2003.tb00114.x, PMID 12931252.

Naresh Chandra Reddy M, Chandra Sekhar KB. Development and validation of gradient RP-HPLC for estimation of impurities in eplerenone tablet dosage form. Int Res J Pharm Appl Sci. 2012 Aug;2:58-75.

Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002 Jul;15(8):709-16. doi: 10.1016/s0895-7061(02)02957-6, PMID 12160194.

White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003 Dec;41(5):1021-6. doi: 10.1161/01.HYP.0000067463.13172.EA, PMID 12682082.

Moore TD, Nawarskas JJ, Anderson JR. Eplerenone: a selective aldosterone Receptor antagonist for hypertension and heart failure. Heart Dis. 2003 May;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb, PMID 14503934.

Patel RP, Patel G, Baria A. Formulation and evaluation of transdermal patch of aceclofenac. Int J Drug Del 2009;1(1):41-51. doi: 10.5138/ijdd.2009.0975.0215.01005.

Das A, Ahmed AB. Formulation and evaluation of transdermal patch of indomethacin containing patchouli oil as a natural penetration enhancer. Asian J Pharm Clin Res. 2017;10(11):320-5. doi: 10.22159/ajpcr.2017.v10i11.20926.

Mishra AD, Khunt DM, Ghayal AH, Patel CN, Shah DR. Formulation and optimization of ethosomes for transdermal delivery of felodipine. Res J Pharm Technol. 2012 May;5(12):1509-17.

Mishra AD, Patel CN, Shah DR. Formulation and optimization of ethosomes for transdermal delivery of ropinirole hydrochloride. Curr Drug Deliv. 2013 Oct 1;10(5):500-16. doi: 10.2174/1567201811310050002, PMID 23410071.

Rao MR, Sonavane V, Kulkarni S, Magar M, Zope A, Karanjkar P. Design of transdermal patch of ketoprofen by full factorial design for the treatment of rheumatoid arthritis. J Drug Delivery Ther. 2019 Mar 15;9(2):197-205. doi: 10.22270/jddt.v9i2.2549.

Lankaranian D, Reis R, Henderer JD, Choe S, Moster MR. Comparison of single thickness and double thickness processed pericardium patch graft in glaucoma drainage device surgery: a single surgeon comparison of outcome. J Glaucoma. 2008 Jan 1;17(1):48-51. doi: 10.1097/IJG.0b013e318133fc49, PMID 18303385.

Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev. 1971;71(6):525-616. doi: 10.1021/cr60274a001.

Nichols L. Step-by-step procedures for melting point determination. Chemistry Libre Text 2021.

Jamakandi VG, Mulla JS, Vinay BL, Shivakumar HN. Formulation, characterization, and evaluation of matrix-type transdermal patches of a model antihypertensive drug. Asian J Pharm. 2009;3(1). doi: 10.4103/0973-8398.49177.

Guyot M, Fawaz F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. Int J Pharm. 2000 Jun 20;204(1-2):171-82. doi: 10.1016/s0378-5173(00)00494-4, PMID 11012001.

Wang J, Ruan J, Zhang C, Ye Y, Cai Y, Wu Y. Development and evaluation of the sinomenine transdermal patch. Pak J Pharm Sci. 2008 Oct 1;21(4):407-10. PMID 18930863.

Aggarwal G, Dhawan S, Harikumar SL. Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine. Pharm Dev Technol. 2013 Aug 1;18(4):916-25. doi: 10.3109/10837450.2011.609993, PMID 21913873.

Parivesh S, Sumeet D, Abhishek D. Design, evaluation, parameters and marketed products of transdermal patches: a review. J Pharm Res. 2010 Feb;3(2):235-40.

Gaikwad KA. Transdermal drug delivery system: formulation aspects and evaluation. Int J PharmTech Res. 2013 Mar;3(4):2140-8.

Darwhekar G, Jain DK, Patidar VK. Formulation and evaluation of transdermal drug delivery system of clopidogrel bisulphate. Asian J Pharm Life Sci. 2011 Jan;1(3):14-20.

Latheeshjlal LP, Phanitejaswini SY, Swapna U, Sarika V, Moulika G. Transdermal drug delivery systems: an overview. Int J Pharmtechn Res. 2011 Mar;3(4):1-8.

Kumar SR, Jain A, Nayak S. Development and evaluation of transdermal patches of colchicine. Pharm Lett. 2012 Apr;4(1):330-43.

Mutalik S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci. 2004 Jun;93(6):1577-94. doi: 10.1002/jps.20058, PMID 15124215.

Mali AD, Bathe R, Patil M. An updated review on transdermal drug delivery systems. Int J Adv Sci Res. 2015 Jan;1(6):244-54. doi: 10.7439/ijasr.v1i6.2243.

Bagchi A, Dey BK. Formulation, in vitro evaluations and skin irritation study of losartan potassium transdermal patches. Iran J Pharm Sci. 2010 Jun;6(3):163-70.

Keleb E, Sharma R, Mosa EB, Zaljahwi AZ. Transdermal drug delivery system design and evaluation. Int J Adv Pharm Sci. 2010 Feb;1:201-11.

Prajapati ST, Patel CG, Patel CN. Formulation and evaluation of transdermal patch of repaglinide. ISRN Pharm. 2011;2011:651909. doi: 10.5402/2011/651909, PMID 22389856.

Kavitha K, Rajendra MM. Design and evaluation of transdermal films of lornoxicam. Int J Pharm Biol Sci. 2011 Jun 30;2(2):54-62.

Furuishi T, Io T, Fukami T, Suzuki T, Tomono K. Formulation and in vitro evaluation of pentazocine transdermal delivery system. Biol Pharm Bull. 2008 Jul 1;31(7):1439-43.

Gutschke E, Bracht S, Nagel S, Weitschies W. Adhesion testing of transdermal matrix patches with a probe tack test-in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2010 Aug 1;75(3):399-404. doi: 10.1016/j.ejpb.2010.03.016, PMID 20350598.

Saroha K, Yadav B, Sharma B. Transdermal patch: A discrete dosage form. Int J Curr Pharm Res. 2011 Apr;3(3):98-108.

Ravikumar R, Ganesh M, Senthil V, Ramesh YV, Jakki SL, Choi EY. Tetrahydro curcumin loaded PCL-PEG electrospun transdermal nanofiber patch: preparation, characterization, and in vitro diffusion evaluations. J Drug Deliv Sci Technol. 2018 Apr 1;44:342-8. doi: 10.1016/j.jddst.2018.01.016.

Pongjanyakul T, Prakongpan S, Priprem A. Acrylic matrix type nicotine transdermal patches: in vitro evaluations and batch-to-batch uniformity. Drug Dev Ind Pharm. 2003 Jan 1;29(8):843-53. doi: 10.1081/ddc-120024180, PMID 14570305.

Jayakumar C, Kumar KD, Nesakumar D, Gandhi NN. Quantitative analysis of theophylline bulk sample using sodium salicylate hydrotrope. Int J Pharm Pharm Sci 2010;2(3):124-5.

Sharma S, Aggarwal G, Dhawan S. Design and evaluation of olanzapine transdermal patches containing vegetable oils as permeation enhancers. Scholars Research Library. 2010 Feb;2(6):84-98.

Gannu R, Vishnu YV, Kishan V, Rao YM. Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. Curr Drug Deliv. 2007 Jan 1;4(1):69-76. doi: 10.2174/156720107779314767, PMID 17269919.

Pathan BI, Setty CM, Gupta VRM. Comparison of the effect of essential oils on the permeation of diclofenac diethylamine through various barriers. Acta Pharm Sci. 2008 Aug;50(3):219-28.

Marwah H, Garg T, Goyal AK, Rath G. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv. 2016;23(2):564-78. doi: 10.3109/10717544.2014.935532, PMID 25006687.

Kunta JR, Goskonda VR, Brotherton HO, Khan MA, Reddy IK. Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin. J Pharm Sci. 1997 Nov;86(12):1369-73. doi: 10.1021/js970161+, PMID 9423148.

Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations. Med Dev Technol. 1990 Dec;1(5):48-55. PMID 10171148.

Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems: part II: system design considerations. Med Dev Technol. 1990 Jul;1(6):28-33. PMID 10171149.

Norton BJ, Strube MJ. Guide for the interpretation of the two-way analysis of variance. Phys Ther. 1986 Apr;66(3):402-12. doi: 10.1093/ptj/66.3.402, PMID 3952157.

Kim HY. Statistical notes for clinical researchers: two-way analysis of variance (ANOVA)-exploring possible interaction between factors. Restor Dent Endod. 2014 Feb;39(2):143-7. doi: 10.5395/rde.2014.39.2.143, PMID 24790929.

Banerjee S, Chattopadhyay P, Ghosh A, Pathak MP, Singh S, Veer V. Acute dermal irritation, sensitization, and acute toxicity studies of a transdermal patch for prophylaxis against ({+/-}) anatoxin-a poisoning. Int J Toxicol. 2013 Apr;32(4):308-13. doi: 10.1177/1091581813489996, PMID 23696561.

Kawahara K, Tojo K. Skin irritation in transdermal drug delivery systems: a strategy for its reduction. Pharm Res. 2007;24(2):399-408. doi: 10.1007/s11095-006-9165-4, PMID 17191093.

Vishwakarma AK, Panda P, Verma NK, Vishwakarma DK, Mishra JN. An overview of transdermal patches. Int J Pharm Rev Res. 2017;7(1):17-23.

Shinde AJ, Shinde AL, More HN. Design and evaluation of transdermal drug delivery system of gliclazide. Asian J Pharm. 2010 Feb;4(2):121-9. doi: 10.4103/0973-8398.68463.

Trivedi D, Goyal A. Formulation and evaluation of transdermal patches containing dexketoprofen trometamol. Int J Pharm Chem Anal. 2020 Oct;7(2):87-97. doi: 10.18231/ j.ijpca.2020.014.

Deepika B, Juveria T, Kandukoori NR, Sarojini S, Sowmya S. Dissolution: A predictive tool for conventional and novel dosage forms. J Pharm Res. 2018 Nov;7(6):113-9.

Khan R, Irchhaiya R. In vitro in vivo evaluation of niosomal formulation of famotidine. Int J Pharm Pharm Sci. 2020 Jan 10:15-22. doi: 10.22159/ijpps.2020v12i3.36210.